Physician profile
Evan Clark
NPI 1083071443
$10,587.04
in general payments reported to CMS, 2019-2025
34 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,592 · 2022: $2,413 · 2023: $2,512 · 2024: $2,386 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,452 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,451.55 |
| Education | $130.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,896.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,434.29 | 2021-2025 | |
| Lilly USA, LLC | $820.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $793.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $700.75 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $621.37 | 2021-2024 | Xarelto |
| Amgen INC. | $544.20 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $527.81 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $446.29 | 2022-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $332.77 | 2021-2023 | |
| Astellas Pharma US INC | $328.70 | 2023-2025 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $287.35 | 2021-2025 | Trintellix |
| Pfizer INC. | $273.58 | 2023-2025 | |
| Axsome Therapeutics, INC. | $200.37 | 2022-2025 | Auvelity, Symbravo |
| Sumitomo Pharma America, INC. | $191.06 | 2023-2025 | Gemtesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $189.93 | 2021-2025 | |
| Horizon Therapeutics Plc | $171.85 | 2021-2022 | |
| Exact Sciences Corporation | $166.29 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $119.41 | 2022 | |
| Dexcom, INC. | $77.31 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $75.64 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.39 | 2022-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $60.63 | 2021 | |
| Inari Medical, INC. | $39.26 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $34.24 | 2023-2024 | Eluvia, Ekosonic |
| Corium, LLC | $34.03 | 2025 | Azstarys |
| Lundbeck LLC | $22.41 | 2023 | Rexulti |
| Inspire Medical Systems, INC. | $19.15 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $19.04 | 2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $18.70 | 2023 | Rexulti |
| Azurity Pharmaceuticals, INC. | $18.66 | 2024 | Edarbi |
| Abbott Laboratories | $17.22 | 2025 | Freestyle Libre 3 |
| Grifols USA, LLC | $16.31 | 2024 | Prolastin-C Liquid |
| Esperion Therapeutics, INC. | $15.60 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.